Literature DB >> 30179109

Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension.

Riccardo Sartoris1, Pierre-Emmanuel Rautou1, Laure Elkrief1, Gaia Pollorsi1, François Durand1, Dominique Valla1, Laurent Spahr1, Sylvain Terraz1, Olivier Soubrane1, François Cauchy1, Valérie Vilgrain1, Maxime Ronot1.   

Abstract

Purpose To determine whether quantification of liver surface nodularity (LSN) provides an estimate of the presence of clinically significant portal hypertension (CSPH) in patients with cirrhosis. Materials and Methods This retrospective study included a training cohort (n = 189) and separate external validation cohort (n = 78), both composed of patients with cirrhosis who underwent abdominal CT and hepatic venous pressure gradient (HVPG) measurement between 2010 and 2016. The LSN score, liver and spleen volumes, liver-to-spleen volume ratio, platelet count to spleen diameter ratio, Iranmanesh score, aspartate amino transferase-to-platelet ratio index, and Fibrosis-4 index were derived from CT images and serum laboratories. The accuracy of the various tests for predicting CSPH was evaluated with area under the receiver operating characteristic curve (AUROC) and compared by using the DeLong test. Student t test and Pearson correlation coefficient were used. Results One hundred eighty-nine patients were analyzed (119 men [mean age ± standard deviation, 57 years ± 11; range, 29-81 years] and 70 women [mean age, 61 years ± 10; range, 34-83 years]; overall mean age, 58 years ± 10; range, 29-83 years). A total of 102 patients (54%) had CSPH. LSN score correlated with HVPG (r = 0.75; P < .001). Patients with CSPH had a higher LSN score than did those without CSPH (3.2 ± 0.6 vs 2.4 ± 0.3; P < .001). A cutoff value of 2.8 had a positive predictive value of 88% for CSPH; the AUROC of LSN was 0.88 ± 0.03. This was higher than that of other available noninvasive tests (DeLong, all P < .001). In the validation cohort, LSN score of 2.8 had a positive predictive value of 86% for CSPH; the AUROC was 0.87 ± 0.04. Conclusion The CT-based liver surface nodularity score demonstrated high diagnostic performance for detecting clinically significant portal hypertension and outperformed multiple other noninvasive tests. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2018        PMID: 30179109     DOI: 10.1148/radiol.2018181131

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

1.  Prediction of post TIPS hepatic encephalopathy: are we there yet?

Authors:  Sanchit Sharma; Ashish Chauhan; Anoop Saraya
Journal:  Hepatol Int       Date:  2021-06-11       Impact factor: 6.047

Review 2.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

3.  CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria.

Authors:  Riccardo Sartoris; Marie Lazareth; Arianna Nivolli; Marco Dioguardi Burgio; Valérie Vilgrain; Maxime Ronot
Journal:  Abdom Radiol (NY)       Date:  2020-09

Review 4.  Portal pressure monitoring-state-of-the-art and future perspective.

Authors:  Gang Xu; Fei Li; Yilei Mao
Journal:  Ann Transl Med       Date:  2019-10

Review 5.  Management of Portal Hypertension.

Authors:  Anand V Kulkarni; Atoosa Rabiee; Arpan Mohanty
Journal:  J Clin Exp Hepatol       Date:  2022-03-21

6.  Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD.

Authors:  Marco Dioguardi Burgio; Riccardo Sartoris; Aurélie Beaufrere; Jules Grégory; Boris Guiu; Chloé Guillot; Pierre-Emmanuel Rautou; Laurent Castera; Mohamed Bouattour; Valérie Paradis; Valérie Vilgrain; Maxime Ronot
Journal:  Eur Radiol       Date:  2021-09-17       Impact factor: 7.034

Review 7.  Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease.

Authors:  Jérémy Dana; Aïna Venkatasamy; Antonio Saviano; Joachim Lupberger; Yujin Hoshida; Valérie Vilgrain; Pierre Nahon; Caroline Reinhold; Benoit Gallix; Thomas F Baumert
Journal:  Hepatol Int       Date:  2022-02-09       Impact factor: 9.029

8.  Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma.

Authors:  Martin Seror; Riccardo Sartoris; Christian Hobeika; Mohamed Bouattour; Valérie Paradis; Pierre-Emmanuel Rautou; Olivier Soubrane; Valérie Vilgrain; François Cauchy; Maxime Ronot
Journal:  Ann Surg Oncol       Date:  2020-09-23       Impact factor: 5.344

9.  Combining hepatic surface nodularity and serum tests better predicts hepatic fibrosis stages in chronic liver disease.

Authors:  Hyo Jung Cho; Jaewon Choi; Bohyun Kim; JeongGil Ko; Joon-Il Choi; Jimi Huh; Jei Hee Lee; Jai Keun Kim
Journal:  Abdom Radiol (NY)       Date:  2021-05-12

10.  Network Meta-Analysis: Noninvasive Imaging Modalities for Identifying Clinically Significant Portal Hypertension.

Authors:  Yang Hai; Weelic Chong; John R Eisenbrey; Flemming Forsberg
Journal:  Dig Dis Sci       Date:  2021-07-17       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.